Parkinson’s Disease cell therapy / Innervace - LARVOL DELTA

Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders (Businesswire) - "Innervace...announced today it has raised up to $40 million in Series A financing. The new funding led by Deerfield Management with participation from founding investor IP Group, Inc., in addition to Penn Medicine, WARF Ventures, and BioAdvance will accelerate efforts to develop Innervace’s lead program, which aims to reconstruct the lost nigrostriatal pathway in patients with Parkinson’s Disease. Additionally, this round of funding enables licensing of a cell source with a specific (A9) dopaminergic phenotype from a research collaboration between UC San Diego and Deerfield Management. Using these cells and a biofabricated scaffold pathway reconstruction strategy differentiates Innervace’s approach from current cell therapy approaches for Parkinson’s."

Financing • CNS Disorders • Parkinson's Disease